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In Brief
A significant impediment in treatment of
leukemia, induced by oncogenic FLT3
and KIT receptors, is inadequate under-
standing of critical signaling pathways
that lead to the development of this dis-
ease. In this study, Chatterjee et al.
show an essential role of FAK/Tiam1/
Rac1/PAK1 pathway in regulating nuclear
translocation of Stat5 leading to leukemo-
genesis, in the context of oncogenic mu-
tations of FLT3 and KIT, and provide mul-
tiple potential therapeutic targets to treat
leukemia.
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Oncogenic mutations of FLT3 and KIT receptors are
associated with poor survival in patients with acute
myeloid leukemia (AML) and myeloproliferative neo-
plasms (MPNs), and currently available drugs are
largely ineffective. Although Stat5 has been impli-
cated in regulating several myeloid and lymphoid
malignancies, how precisely Stat5 regulates leuke-
mogenesis, including its nuclear translocation to
induce gene transcription, is poorly understood. In
leukemic cells, we show constitutive activation of
focal adhesion kinase (FAK) whose inhibition re-
presses leukemogenesis. Downstream of FAK, acti-
vation of Rac1 is regulated by RacGEF Tiam1, whose
inhibition prolongs the survival of leukemic mice. In-
hibition of the Rac1 effector PAK1 prolongs the sur-
vival of leukemicmice in part by inhibiting the nuclear
translocation of Stat5. These results reveal a leu-
kemic pathway involving FAK/Tiam1/Rac1/PAK1
and demonstrate an essential role for these signaling
molecules in regulating the nuclear translocation of
Stat5 in leukemogenesis.
INTRODUCTION
Acute myeloid leukemia (AML) is a lethal disease characterized
by uncontrolled growth of myeloid cells and is predominantly a
disease of the elderly. Little progress has been made in terms
of standard-of-care treatment for AML, which has essentially re-
mained the same over decades. Long-term survival is observed
in 30% of younger patients and 5% of older patients greater
than 60 years of age. Internal tandem duplications (ITD), in-frame
insertions, or duplication of amino acids near the juxtamembrane
domain of FLT3 have been observed in 25%–30% of all AMLCell Repatients and confer a poor prognosis (Kottaridis et al., 2001).
Likewise, Gleevec-resistant activation loop mutations of KIT
(KITD816V) are found in a number of patients with core-binding
factor-AML and 95% patients with systemic mastocytosis
(SM) and confer poor overall survival (Beghini et al., 2004).
Both FLT3ITD and KITD816V receptors are constitutively phos-
phorylated (Kiyoi et al., 2002; Spiekermann et al., 2003) and
induce growth in a ligand-independent manner. Whereas effort
has been devoted to the development of FLT3 and KIT inhibitors,
as single agents, the efficacy of these inhibitors is limited and in
some cases results in drug resistance (Smith et al., 2012). Given
that direct targeting of FLT3ITD or KITD816V has met with little
success, signaling pathways downstream from FLT3ITD/
KITD816V provide attractive alternate targets for treating hema-
tologic malignancies involving these receptors.
Overexpression of focal adhesion kinase (FAK) in up to 50% of
AML-patient-derived cells, but not in normal cells, has been
observed, and FAK is hyperphosphorylated on Y397 in a number
of patients. FAK+ AML cells show greater migration and resis-
tance to daunorubicin compared to FAK cells, and FAK expres-
sion correlates with high blast cell counts, early death, and
shorter survival rate (Despeaux et al., 2011; Recher et al., 2004;
Li and Hua, 2008). Presence of phosphorylated (p) pStat5 in
newly diagnosed AML patients is also associated with poor over-
all survival (Brady et al., 2012). Constitutive activation of pStat5 is
observed in 100%of SMpatients bearing theKITD816Vmutation
(Baumgartner et al., 2009). A strong correlation between the
presence of pStat5 and FLT3ITD mutations is seen in AML pa-
tients, and FLT3ITDexpression results in constitutive Stat5 phos-
phorylation (Obermann et al., 2010; Spiekermann et al., 2003;
Choudhary et al., 2005, 2007). Mutating the binding sites for
Stat5 in the FLT3ITD abrogates the development of myeloprolif-
erative neoplasms (MPNs) (Rocnik et al., 2006). Taken together,
studies suggest that FLT3ITD/KITD814V, FAK, and Stat5 may be
involved in regulating a critical pathway in AML and MPNs; how-
ever, the relationship between these signaling molecules in the
context of leukemogenesis is not fully understood. Importantly,ports 9, 1333–1348, November 20, 2014 ª2014 The Authors 1333
A 
C 
G 
E 
F 
B 
D 
H (i) (ii) (iii) 
MK
Figure 1. FAK Is Constitutively Phosphory-
lated in FLT3 and Activating KITD814V
Oncogene-Bearing Cells
(A) Serum-starved 32D cells expressing FLT3ITD
and FLT3WTwere treated with DMSO (lanes 1 and
5), F-14 (lanes 2 and 6), IL-3 (lanes 3 and 7), or F-14
followed by IL-3 (lanes 4 and 8). An equal amount
of protein was subjected to western blot analysis
and probed with phospho-FAK (Y397) antibody
(n = 3). ‘‘MK’’ denotes lane with protein ladder.
(B) 32D cells expressing KITWT or KITD814V were
treatedwith F-14 (n = 2) and analyzed as described
in (A).
(C) 32D cells expressing FLT3WT were treated
with F-14 (lane 2) or stimulated with FLT3 ligand
(FL) (lane 3) and analyzed as described in (A).
(D) 32D cells expressing FLT3WT or FLT3ITD were
treated with FLT3ITD inhibitor AC220 and
analyzed for activated FLT3 (pY589/591).
(E) 32D cells expressing FLT3ITDwere treatedwith
F-14 (lane 2) or with AC220 (lane 3; n = 2) and
analyzed as above.
(F) Lysates from primary FAK/-deficient or WT
BM cells expressing KITD814V or empty vector
were analyzed for activated FAK.
(G) FLT3ITD+ve AML patient sample was analyzed
for activated FAK (n = 2).
(H) 32D cells expressing FLT3ITD were treated
with Y-11 and subjected to flow cytometry anal-
ysis. The percentage of cells show activated FAK
under basal conditions in FLT3WT (i), FLT3ITD
vehicle-treated cells (ii), and FLT3ITD treated with
Y-11 (iii). n = 2.although Stat5 has been implicated in regulating several hemato-
logic malignancies, how precisely activation of Stat5 is regulated
in the cytosol or in the nucleus of leukemic cells and what are the
signalingmolecules involved in its nuclear import in the context of
AML or MPN remains unclear. Here, we reveal a leukemic
pathway involving FAK/Tiam1/Rac1/PAK1 and demonstrate an
essential role for these signaling molecules in regulating the nu-
clear translocation of Stat5 in leukemogenesis.
RESULTS
FAK Is Constitutively Phosphorylated in FLT3ITD- and
KITD814V-Expressing Cells
32D cells expressing the wild-type (WT) FLT3 or KIT receptor
(FLT3WT or KITWT) or its oncogenic version (FLT3ITD or
KITD814V) were starved and treated with a FAK-specific inhibi-
tor F-14 (Golubovskaya et al., 2008). Enhanced activation of
FAK was observed in FLT3ITD-bearing cells compared to con-
trols (Figure 1A, lane 1 versus 5), which was inhibited in the pres-1334 Cell Reports 9, 1333–1348, November 20, 2014 ª2014 The Authorsence of F-14 (Figure 1A, lane 6 versus 5).
Similar results were observed in cells ex-
pressing KITWT and KITD814V receptors
(Figure 1B). To assess if activation of FAK
was restricted to oncogenic FLT3- and
KIT-receptor-expressing cells, same cells
were stimulated with interleukin (IL)-3 toactivate the IL-3 receptor and analyzed for FAK activation. As
seen in Figure 1A (lane 3), IL-3 stimulation also resulted in activa-
tion of FAK, which was inhibited in the presence of F-14 (Fig-
ure 1A, lane 4). Similar results were observed upon treatment
of cells with FLT3 ligand (FL) (Figure 1C, lane 1 versus 3). To
assess the direct involvement of FLT3ITD in FAK activation, cells
were treated with AC220, a potent FLT3ITD inhibitor (Smith et al.,
2012). Treatment of FLT3ITD cells with AC220 inhibited the acti-
vation of FLT3ITD (Figure 1D, lane 3 versus 4) and also resulted in
reduced FAK activation (Figure 1E, lane 1 versus 3). To rule out
the nonspecific effects of F-14 on FAK inhibition, we utilized a
genetic approach. WT bone marrow (BM) cells expressing
KITD814V demonstrated increased levels of active FAK com-
pared to controls, whereas FAK/ BM cells showed absence
of FAK expression (Figure 1F). FLT3ITD+ve AML-patient-derived
cells also demonstrated constitutive FAK activation, which was
inhibited in the presence of F-14 (Figure 1G). Figures 1D and
S8D show the expression of total FLT3 and KIT receptors. We
also performed intracellular staining to determine the effect of
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B Figure 2. Inhibition of FAK Suppresses the
Constitutive Growth of Oncogenic FLT3-
and KIT-Bearing Cells
(A and B) BaF3 (A) or 32D (B) cells expressing
FLT3WT or FLT3ITD were cultured for 48 hr in the
presence or absence of F-14 or Y-11 in replicates
of four and subjected to a thymidine incorporation
assay. CPM, counts per minute.
(C) BaF3 cells coexpressing FRNK and either
FLT3ITD or FLT3WT were subjected to thymidine
incorporation assay as in (A) and (B).
(D) WT or FAK/ BM cells expressing FLT3ITD or
FLT3WT were subjected to proliferation assay in
the absence of growth factors as described in (A)
and (B).
(E and F) MV4-11 cells expressing endogenous
levels of FLT3ITD (E) or HL60 cells harboring
FLT3WT (F) were subjected to thymidine incorpo-
ration assay in presence of Y-11.
(G and H) 32D cells expressing KITD814V orWTKIT
(G) and HMC1.2 human leukemic cells line
harboring KIT (D816V + G560V) mutations (H) were
cultured in the absence or presence of Y-11 and
subjected to thymidine incorporation assay.
Thymidine incorporation is depicted on y axis as
mean ± SD; *p < 0.05. NGF/No GF, cells grown in
presence of no growth factors/cytokines. Data are
representative of at least three independent ex-
periments.Y-11; another FAK-specific inhibitor (Golubovskaya et al., 2012)
on FLT3ITD mediated repression of FAK. As seen in Figure 1H,
the percentage of cells showing activated FAK was significantly
higher in FLT3ITD-expressing cells (83.1%, middle panel) as
compared to WT (19.2%; left versus middle panel). Treatment
of FLT3ITD cells with Y-11 inhibited the activation of FAK
(69.7%, right panel) and correspondingly increased the levels
of unphosphorylated FAK (30.3%) in comparison to vehicle
treated (16.9%; right panel versus middle panel). These results
suggest that FAK is hyperactive in FLT3 and KIT oncogene-
bearing cells and pharmacologic inhibition or genetic loss of
FAK can repress the activation of FAK in these cells.
Inhibition of FAK Suppresses the Constitutive Growth of
Oncogenic FLT3- and KIT-Expressing Cells
We assessed the functional significance of constitutive activa-
tion of FAK in FLT3ITD-expressing cells. As seen in Figure 2A,Cell Reports 9, 1333–1348, Notreatment of BaF3 cells with F-14 signifi-
cantly repressed the ligand-independent
growth of FLT3ITD-bearing cells in a
dose-dependent manner, with minimal ef-
fect on FLT3WT-expressing cells. Similar
growth repression was seen in 32D cells
treated with Y-11 (Figure 2B). Expression
of FRNK, a dominant negative version of
FAK (Zhao and Guan, 2009), also
repressed the ligand-independent growth
of FLT3ITD-expressing cells (Figure 2C),
which was partly a result of reduced sur-
vival (Figures S1A and S1B). Expressionof FRNK in FLT3 cells is shown in Figure S8D. Although these re-
sults suggest an essential role for FAK in ligand-independent
growth of FLT3ITD-expressing cells, a direct role of FAK was as-
certained by complete ablation of FAK. As seen in Figure 2D,
expression of FLT3ITD in WT BM cells (FAK+/+) demonstrated
ligand-independent growth, which was significantly repressed
in FAK/ cells. We also assessed whether targeting hyperac-
tive FAK in cell lines derived from human leukemic patients
shows similar effects. We used MV4-11 and HL60 cells that ex-
press the FLT3ITD andWT receptors, respectively. Treatment of
MV4-11 cells with Y-11 showed a dose-dependent repression of
constitutive growth (Figure 2E), whereas no such effect was
observed in HL60 cells (Figure 2F).
To assess whether FAK plays a similar role in cells bearing an
oncogenic form of KIT (KITD816V in humans and KITD814V in
mouse), we used 32D cells expressing WTKIT or KITD814V. As
seen in Figure 2G, treatment of these cells with Y-11 resultedvember 20, 2014 ª2014 The Authors 1335
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Figure 3. AC220-Resistant FLT3 Mutations,
Primary AML FLT3ITD+ Cells, or KITD816V+
SM Cells Are Sensitive to FAK Inhibition
(A) BaF3 cells bearing FLT3ITD or FLT3 receptors
with acquired AC220-resistant mutations in the
kinase domain (D835Y, F691L, and D835V) were
subjected to proliferation assay as described in
Figure 2; *p < 0.05.
(B and C) Primary AML patient cells positive for
FLT3ITD mutation (AML nos. 1–4) (B) or primary
KITD816V(+) or KITD816V() SM cells (C) were
treated with indicated concentrations of F-14 or Y-
11. After 48 hr, proliferation assay was performed.
Bars denote mean ± SD; *p < 0.05.in growth repression of KITD814V-expressing cells. Similar re-
sults were observed upon Y-11 treatment of HMC1.2 cells de-
rived from a human mastocytosis patient bearing the activating
KIT mutation (Figure 2H). These results show that FAK plays an
essential role in supporting the constitutive growth of FLT3 and
KIT oncogene-bearing hematopoietic cells, which is modulated
by pharmacologic or genetic inhibition of FAK.
AC220-Resistant ‘‘Driver’’ Mutations of FLT3 Are
Sensitive to FAK Inhibition
Recent translational studies validated FLT3ITDmutations in AML
to function as ‘‘driver,’’ but not ‘‘passenger,’’ mutations (Smith
et al., 2012). Smith et al. demonstrated the presence of point mu-
tations at three residues within the kinase domain of FLT3ITD
that conferred resistance to AC220, an inhibitor of FLT3 and
KIT. Acquisition of AC220-resistant substitutions at two of these
residues was observed in all FLT3ITD+ AML patients with ac-
quired resistance to AC220, thus validating FLT3ITD to function1336 Cell Reports 9, 1333–1348, November 20, 2014 ª2014 The Authorsas a driver mutation and a critical thera-
peutic target in AML. We assessed
whether these mutants were sensitive to
FAK inhibition. As seen in Figure 3A,
AC220-resistant FLT3-kinase-domain-
mutant (D835Y, F691L, and D835V)-
induced growth is inhibited by F-14.
AML FLT3ITD+ and KITD816V+
SM-Patient-Derived Cells Are
Sensitive to FAK Inhibition
Next, we assessed whether inhibition of
FAK in primary FLT3ITD+ AML cells in-
hibits their growth. We examined cells
derived from 16 independent patients.
Data from four representative patients
are shown. In Figure 3B, a dose-depen-
dent reduction in the growth of all
FLT3ITD+ AML cells was observed in
the presence of F-14 and Y-11. Likewise,
SM-patient-derived cells positive for
KITD816V mutation also demonstrated
significantly greater growth reduction
relative to patients lacking the expression
of KITD816V (Figure 3C). These resultsdemonstrate that FAK is indeed hyperactive in FLT3ITD- and
KITD816V-expressing cells and its inhibition is associated with
enhanced apoptosis and growth repression.
FAK and Rac1 Modulate the Nuclear Translocation
of Active Stat5 in FLT3 and KIT Oncogene-Expressing
Cells
In an effort to identify downstream targets of FAK that might
contribute to FLT3ITD-induced growth and enhanced survival,
we examined the activation of phosphatidylinositol 3-kinase
(PI3K), ERK mitogen-activated protein kinase (MAPK) as well
as Rac guanosine triphosphatases (GTPases). In nonhemato-
poietic cell types, all three pathways have been shown to be
regulated by FAK (Gabarra-Niecko et al., 2003; Yin, 2011). We
found constitutive and enhanced activation of Rac1 in
FLT3ITD-bearing cells relative to FLT3WT-bearing cells (Fig-
ure 4A; lanes 1 and 2 versus 4 in control [CT] panel). Expression
of FRNK in FLT3ITD-expressing cells significantly inhibited the
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Figure 4. Rac1 Is a Downstream Effector
of FAK in FLT3ITD-Bearing Oncogenic
Pathway
(A) BaF3 (lane 1) or 32D (lane 2) cells expressing the
FLT3WT receptor or FLT3ITD both alone or in
combination with FRNK were starved and sub-
jected to a Rac activation assay. These cells were
either vehicle-treated alone (upper panel [CT]) or
with F-14 (lower panel; n = 2).
(B and C) MV4-11 cells expressing endogenous
FLT3ITD (B) and AML patient FLT3ITD+ cells (C)
were subjected to Rac activation assay as
described in (A).
(D) FLT3ITD-bearing BM cells in the setting of FAK
deficiency were subjected to Rac activation assay
as in (A) (n = 2).
(E) 32D FLT3ITD cells expressing shRNAs target-
ing FAK (lanes 2 and 3) and control shRNA (lane 1)
were subjected to Rac1 activation assay as
described in (A).constitutive activation of Rac (Figure 4A; lane 3, CT panel).
Furthermore, treatment of these cells with F-14 abolished Rac
activation (lanes 1–4 upper CT panel versus lanes 1–4 lower
[F-14] panel; Figure 4A). A similar reduction in Rac activation
was also observed in FLT3ITD+ve human leukemic MV4-11 cells
and FLT3ITD+ AML-patient-derived cells, respectively (Figures
4B and 4C) as well as in FAK/-deficient cells expressing
FLT3ITD (Figure 4D). Small hairpin RNA (shRNA)-mediated
downregulation of FAK in FLT3ITD-bearing cells also showed
similar results (Figure 4E). These results suggest that FAK plays
a role in the activation of Rac1 in FLT3ITD-bearing cells. Con-
sistent with these observations, treatment of cells with a Rac1
inhibitor NSC23766 repressed the constitutive growth of
FLT3ITD+ AML-patient-derived cells and of MV4-11 leukemic
cells expressing the FLT3ITD receptor (Figures S1C and S1D).
HL60 cells that express the FLT3WT receptor were used as a
negative control (Figure S1E). Similar findings were observed inCell Reports 9, 1333–1348, NoFLT3ITD-bearing cells expressing a
dominant-negative version of Rac
(RacN17; Figure S1F).
Active Stat5 is thought to play an
essential role in regulating the transforma-
tion of FLT3 and KIT oncogene-bearing
cells (Baumgartner et al., 2009; Brady
et al., 2012). Although Stat5 is a transcrip-
tion factor, mechanism(s) involved in the
transport of this molecule in and out of
the nucleus in oncogene-bearing cells re-
mains poorly understood. We therefore
performed cellular fractionation assays
to determine the mechanism(s) behind
active Stat5 translocation into the nucleus
mediated by Rac1 and its upstream acti-
vator FAK in oncogene-bearing cells. We
found active Stat5 in the nuclear fractions
of FLT3ITD-bearing cells, which was
associated with enhanced presence of
Rac1, as compared with cells expressingFLT3WT (Figure 5A, lane 1 versus 3). To determine whether nu-
clear translocation of Stat5 could be mimicked in FLT3WT-ex-
pressing cells upon cytokine stimulation, cells were treated
with IL-3 and analyzed for Stat5 and Rac1 localization. As seen
in Figure 5A (lane 2), addition of IL-3 resulted in activation of
FLT3WT-mediated Stat5-Rac1 nuclear localization. Next, we
assessed if the effect of FAK inhibition could be overcome
after ligand stimulation. FLT3ITD-expressing cells were treated
with FLT3 ligand, followed by treatment with F-14. As seen in
Figure 5B, stimulation of FLT3ITD with its ligand FL resulted
in a modest increase in nuclear localized active Stat5 and
Rac1 (Figure 5B, lane 1 versus 3; Zheng et al., 2011), which
was repressed in the presence of F-14 (Figure 5B, lane 4). A
similar reduction in the activation of Stat5 and accumulation
of Rac1, respectively, was noted in the nuclear fractions of pri-
mary FLT3ITD+ AML (Figure S2A), KITD816V+ mastocytosis
(HMC1.2; Figure 5C), and AML-patient-derived cells (MV4-11)vember 20, 2014 ª2014 The Authors 1337
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Figure 5. FAK Regulates the Translocation of Active Stat5 and Rac1 to the Nucleus in FLT3ITD- and KITD816V-Expressing Cells
(A) 32D cells expressing FLT3ITD or FLT3WT were serum starved and subjected to fractionation assays and nuclear and cytosolic fractions analyzed for levels of
active Stat5 (pY694), total Stat5, and Rac1.
(B) 32D cells expressing FLT3ITD were subjected to fractionation assays after treatment with DMSO control, F-14, FL, or with F-14 followed by FL (B; n = 3).
(C) HMC1.2 cells bearing KITD816V+G560V mutations were subjected to fractionation assay as described in (A).
(D) MV4-11 and HL60 cells derived from leukemia patients harboring endogenous FLT3ITD and FLT3WT mutations were subjected to fractionation assay in
presence of F-14 or Y-11 as in (A).
(legend continued on next page)
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treated with F-14 (Figure 5D). HL60 cells that express the
FLT3WT receptor served as a negative control (Figure 5D, right
panels). AC220-resistant driver mutations of FLT3 also de-
monstrated reduced nuclear accumulation of active Stat5 and
total Rac1, respectively, when treated with F-14 (Figure S2B).
Although we did not observe inhibition in the activation of
MAPK or PI3K/Akt pathway in FLT3ITD-bearing cells lacking
FAK or in which FAK was inhibited, we nonetheless directly
examined the contribution of these pathways in the nuclear
translocation of Stat5 and total Rac1. We performed a fraction-
ation assay in the presence of MEK (PD98059), Raf (PLX4720),
or Akt (124005) inhibitor and observed no significant inhibition
of Rac1 or active Stat5 nuclear translocation (Figure S2C). Raf
and MEK inhibitors also failed to repress the constitutive growth
of FLT3ITD-bearing cells (Figures S2D and S2E).
A direct role for FAK in regulating the translocation of active
Stat5 can be seen in Figure S2F. Expression of FLT3ITD failed
to translocate active Stat5 and total Rac1 to the nucleus in
FAK/-deficient BM cells (Figure S2F, lane 1 versus 2). The
expression of FLT3 receptor in WT (FAK+/+) and FAK/ BM
cells is shown in Figure S8E. To further understand the mecha-
nism behind FAK-regulated Stat5 translocation in FLT3 and KIT
oncogene-bearing cells in an in vivo setting, we used cells
derived directly from mice that were transplanted with BM from
WT (FAK+/+) and FAK-deficient (FAK/) mice expressing
KITD814V. Mice transplanted with WTFAK BM cells expressing
KITD814V came down with disease significantly earlier than
FAK/ KITD814V mice (Figure 7G), at which point time-point-
matched control mice (FAK/ KITD814V) were euthanized
and BM cells harvested from both groups of mice and subjected
to cellular fractionation analysis. As seen in Figure 5E (lane 1
versus 2), and consistent with our in vitro findings (Figure S2F),
genetic ablation of FAK in vivo inhibited the nuclear translocation
of active Stat5 and Rac1 in KITD814V-bearing BM-derived
leukemic cells. Furthermore, similar results were also observed
after F-14 treatment of leukemic mice transplanted with BM
cells expressing KITD814V. As seen in Figure 5F, BM cells
derived from leukemic mice bearing the KITD814V mutation
that were treated with F-14 also showed a reduction in Stat5
activation and nuclear accumulation of Rac1, as compared to
cells derived from vehicle (DMSO)-treated mice (Figure 5F,
lane 1 versus 2).
Active Stat5 downstream of FLT3ITD translocates to the
nucleus to bind DNA and express Stat5-responsive genes like
c-Myc and BclXL that play a crucial role in leukemogenesis (Li
et al., 2007; Zhang et al., 2000). We next performed quantitative
RT-PCR (qRT-PCR) analysis to determine the relative expression
of c-Myc and BclXL genes in FLT3ITD cells treated with F-14. As
seen in Figures 5G and 5H, a significant reduction in the expres-
sion of Stat5-responsive genes c-Myc and BclXL was observed(E) Fractionation assays were performed in BM cells harvested from primary trans
or FAK-deficient (FAK/) background (n = 2).
(F) Fractionation assay from BM cells harvested from F-14- or DMSO (vehicle)-
expression and Rac1 expression in the nuclear and cytosolic fractions is indica
loading control. MK denotes lane with protein ladder.
(G and H) qRT-PCR analysis of relative mRNA expression levels of Stat5 respons
(DMSO; n = 2); *p < 0.05.
Cell Reupon FAK inhibition. Similar results were observed in FAK/
FLT3ITD cells (Figures S3A and S3B). To ascertain whether
FAK also regulates the nuclear association between Rac1 and
Stat5, besides directly activating Rac1, F-14-treated nuclear
fractions were subjected to Rac1 immunoprecipitation assay.
As seen in Figure 6A, the amount of active Stat5 that interacts
with Rac1 was significantly reduced upon treatment of FLT3ITD
cells with F-14 (Figure 6A, lane 1 versus 2). These results explain
our initial observation demonstrating reduced levels of total
Rac1 and active Stat5 in nuclear fractions of FLT3ITD-bearing
cells in which FAK activation was repressed and is directly a
consequence of FAK’s role in the activation of Rac1 and more
importantly its association and subsequent translocation with
active Stat5 into the nucleus. To further assess whether FAK reg-
ulates the association between active Rac1 and active Stat5, we
performed active Rac1 pull-down assay from WT and FAK/
BM cells expressing FLT3ITD and analyzed for active Stat5 bind-
ing. As seen in Figure 6B, increased levels of active and total
Stat5 protein were bound to activated Rac1 in WT (FAK+/+)
BM cells (lane 1), which was reduced in FAK-deficient (FAK/)
FLT3ITD-bearing cells (lane 2). Taken together, these findings
suggest that first FAK regulates the formation of an active
Rac1-active Stat5 complex and second it modulates the translo-
cation of Rac1-Stat5 complex into the nuclear compartment.
Because Rac1 contains a functional nuclear localization signal
and also forms a complex with active Stat5 in the nucleus, we
next investigated the role of Rac1 in nuclear translocation of
active Stat5 in FLT3ITD-bearing cells. Cells were treated with or
without Rac inhibitor NSC23766 and subjected to a fractionation
assay. Levels of active Stat5, alongwith total Rac1, were reduced
in FLT3ITD cells treated with NSC23766 (Figure S3C). Likewise,
cells coexpressing FLT3ITD along with a dominant-negative
form of Rac1 (Rac1N17) showed reduced levels of active Stat5
in the nuclear fractions (Figure S3D). Equal expression levels of
GFP-Rac1N17 in FLT3ITD and WT cells can be seen in Figures
S3E and S3F. As seen in Figure 6C (lane 1 versus 2), robust levels
of active Stat5 were present in nuclear fractions of FLT3ITD-ex-
pressing Rac1+/+ BM cells, whereas a significant reduction in
the levels of nuclear localized active Stat5 was observed in
Rac1/ BM cells, with no detectable levels of Stat5 activation
in FLT3WT-bearing cells. These results demonstrate an essential
role for Rac1 in the translocation of active Stat5 into the nucleus.
RacGEF Tiam1 Is Essential for FLT3ITD-Induced
Leukemic Development in Mice
To identify Rac guanine nucleotide exchange factors (GEFs)
involved downstream of FAK in activating Rac1 in FLT3ITD-
bearing cells, we analyzed the role of Tiam1. We ascertained
whether Tiam1 is active in cells bearing FLT3ITD. As seen in Fig-
ure 6D, increased levels of active Tiam1 were observed inplanted mice cohorts transplanted with KITD814V in a wild-type FAK (FAK+/+)
treated primary transplant mice cohorts. The level of Stat5 phosphorylation/
ted. Expression of GAPDH was used as an indicator of cytosolic marker and
ive genes c-Myc (G) and BclXL (H) in FLT3ITD cells treated with F-14 or vehicle
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Figure 6. Downstream of FAK, Tiam1 Regulates the Activation of Rac1 and Subsequent Translocation of Active Stat5 to the Nuclear
Compartment to Develop Leukemia in Mice
(A) Nuclear fractions from F-14-treated FLT3ITD- and FLT3WT-bearing cells were subjected to Rac1 immunoprecipitation assay to assess the level of Rac1
binding to active Stat5. Level of active Stat5 (pY694) and total Stat5 and Rac1 were analyzed.
(B) Active Rac1 fractions from WT and FAK/-deficient BM cells expressing FLT3ITD were determined, along with levels of active and total Stat5. Total Rac1
levels are shown in the lowermost panel (n = 2).
(C) Fractionation assay was performed using WT and Rac1/ BM cells expressing FLT3ITD or FLT3WT receptors. Nuclear and cytosolic fractions were
analyzed as described above. GAPDH was used as a loading control and cytosolic marker (n = 3). MK denotes lane with protein ladder.
(legend continued on next page)
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FLT3ITD-bearing cells compared to FLT3WT-expressing cells
(lane 1 versus 3), which was attenuated upon treating these cells
with F-14 (lane 1 versus 2). Further, F-14 treatment perturbed the
interaction betweenRac1and Tiam1 (Figure 6E). Having observed
the presence of Tiam1 in active Rac1 complex in FLT3ITD-bearing
cells and the perturbation of this association upon FAK inhibition,
we next examined the functional significance of Tiam1 in
FLT3ITD-induced transformation. We knocked down Tiam1 using
shRNA in cells bearing FLT3ITD (Figure S3G). Cells bearing
FLT3ITD and Tiam1 shRNA showed significant reduction in
constitutive growth in comparison to cells bearing scrambled
shRNA (Figure S3H). Moreover, when FLT3ITD and Tiam1shRNA
coexpressing cells were subjected to a fractionation assay, the
levels of active Stat5 and total Rac1 in nuclear fractions were
significantly reduced compared to scrambled shRNA-expressing
cells (Figure 6F, lane 1 versus 2–5). As shown in Figure 6G (lane 1
versus 2–4), knockdownof Tiam1 significantly inhibited the activa-
tion of Rac1 compared to cells coexpressing FLT3ITD and scram-
bled shRNA. These results indicate that Tiam1 plays an important
role in the activation of Rac1 in FLT3ITD-expressing cells, which in
turn regulates the nuclear translocation of the Rac1/Stat5 com-
plex. To further investigate the role of Tiam1 in FLT3ITD-induced
leukemogenesis, we performed transplantation experiments. Fig-
ure 6H shows that mice transplanted with FLT3ITD and Tiam1
shRNA survived significantly longer compared to mice trans-
planted with FLT3ITD and scrambled vector (*p < 0.01).
Inhibition of FAK Delays the Onset of FLT3ITD- and
KITD814V-Induced MPN Development and Prolongs the
Survival of Mice
We next examined the in vivo impact of FAK inhibition on
FLT3ITD- and KITD814V-induced leukemogenesis. Although
mice bearing FLT3ITD cells treated with DMSO died within
30 days posttransplant, mice treated with F-14 showed signifi-
cantly prolonged survival (Figure 7A). F-14-treated mice showed
significantly reduced spleen weight (Figures 7B and 7C) and
demonstrated absence of lesions in lungs compared to DMSO-
treated mice (Figures S4A and S4B). Histopathologic analysis
showed leukemic infiltration of myeloid cells and destruction of
alveolar architecture in lungs and of normal architecture in
spleens of DMSO-treated mice but significant improvement in
the F-14-treated mice (Figures S4C and S4D). Moreover, F-14-
treated mice also showed reduced percentage of leukemic cells
in tissues (peripheral blood and spleen) as determined by the
presence of GFP-positive cells (Figures S4E and S4F), relative
to vehicle-treated mice. Likewise, F-14 treatment of mice trans-
planted with cells expressing KITD814V survived significantly
longer than vehicle-treated mice (Figure S5A; *p < 0.01). We
next assessed these findings in mice transplanted with primary(D) 32D FLT3ITD and FLT3WT cells were treated with DMSO or with F-14 and su
(E) 32D FLT3ITD and FLT3WT cells were subjected to Tiam1 IP in presence or
(IP:Tiam1 panels). Lower two panels (lysate [input]) depict the total protein levels
(F) 32D cells coexpressing FLT3ITD and Tiam1 shRNA or scrambled shRNA wer
were analyzed for the levels of active Stat5 (pY694), total Stat5 and Rac1, and n
(G) 32D cells coexpressing FLT3ITD and Tiam1 shRNAs (lanes 2–4) or scrambled
active and total Rac1 are shown in the upper and lower panels, respectively.
(H) Kaplan-Meier survival curve of mice transplanted with 32D cells coexpressin
Cell ReBM cells expressing KITD814V. One cohort of mice was treated
with F-14 and the other with vehicle (DMSO). As seen in Fig-
ure 7D, white blood cell (WBC) counts remained constant over
the entire duration of F-14 treatment in KITD814V-bearing mice
(6 weeks), whereas KITD814V-bearing mice treated with vehicle
demonstrated a steady rise in WBC counts over time, a hallmark
of MPN development and progression. At the end of 6 weeks, all
mice were euthanized and analyzed. As seen in Figures 7E and
7F, vehicle-treated mice demonstrated significant enlargement
of spleen compared to F-14-treated mice. Collectively, these
data support the observation that targeting FAK rescues the
development of FLT3ITD- and KITD814V-induced MPN in vivo.
To further investigate the role of FAK in FLT3ITD-induced MPN,
we knocked down FAK expression using shRNA in cells bearing
FLT3ITD and transplanted into mice as described in Figure 7A.
Knockdown of FAK not only repressed the constitutive growth
of FLT3ITD-bearing cells (Figure S5B), but more importantly,
mice transplanted with cells coinfected with FLT3ITD and FAK
shRNA survived significantly longer compared to mice trans-
planted with FLT3ITD and scrambled vector (Figure S5C; *p <
0.025). To rule out nonspecific effects of F-14 and diminished,
but not absolute, effects of shRNA-mediated knockdown of
FAK, we performed transplantation studies using primary BM
cells from WT (FAK+/+) and FAK/-deficient mice expressing
the oncogenic KITD814V receptor. As seen in Figure 7G, genetic
ablation of FAK significantly prolonged the survival of leukemic
mice (FAK/ KITD814V) compared to controls (FAK+/+
KITD814V). Leukemic mice harboring the KITD814V oncogene
in the FAK/ background demonstrated reduced spleen size
(Figures 7H and 7I) and WBC counts relative to controls (Fig-
ure S5D). To further ascertain whether targeting FAK in the
context of KITD814V-induced MPN inhibits the growth of cells
that give rise to leukemia, we performed secondary transplants
using BM cells derived from the primary cohorts. As seen in Fig-
ure 7J, mice transplanted with BM cells from primary donor
harboring KITD814V in a FAK-deficient background (FAK/
KITD814V) survived significantly longer than mice transplanted
with BM from WT background (FAK+/+ KITD814V). The pro-
longed survival of these mice correlated with reduced sple-
nomegaly (Figures 7K and 7L). Importantly, loss of FAK in
hematopoietic stem cells did not impair the engraftment or the
self-renewal of these cells (Lu et al., 2012).
Targeting PAK1 Inhibits the Nuclear Translocation
of Active Stat5
To determine the functional role of p21-activated kinase (PAK), a
downstream effector of Rac1, in Stat5 regulation and leukemo-
genesis, we utilized a recently described allosteric PAK inhibitor,
IPA-3 (Deacon et al., 2008). As seen in Figure 8A (lane 5 versus 7),bjected to Tiam1 activation assay (n = 2).
absence of F-14. Samples were analyzed for amount of Rac1-binding Tiam1
of Rac1 and Tiam1 (n = 2).
e subjected to cellular fractionation assay, and nuclear and cytosolic fractions
uclear marker/loading control PARP-1.
shRNA (lane 1) were subjected to active Rac1 pull-down assay. The amount of
g FLT3ITD and Tiam1 shRNA (n = 5) or scrambled shRNA (n = 5); *p < 0.01.
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Figure 7. In Vivo Inhibition of FAK Delays the Development of MPN in Mice Transplanted with FLT3ITD- and KITD814V-Bearing Cells
(A) C3H/HeJ mice were transplanted with 32D cells bearing FLT3ITD and treated with 20 mg/kg body weight F-14 for 28 days.
(B and C) Kaplan-Meier survival analysis of vehicle- (n = 14) versus F-14 (n = 15)-treated mice showed significant increase in overall survival (*p < 0.02) and
significant reduction of spleen size and weight in F-14-treated mice as compared to vehicle (DMSO) control-treated mice.
(D) BoyJ mice were irradiated and transplanted with 50 fluorouracil (5-FU)-treated BM cells expressing KITD814V. Mice were randomly divided into two groups
and treated with vehicle (DMSO; n = 7) or F-14 (n = 7) after 3 weeks posttransplantation, for 6 weeks. Peripheral blood frommice was analyzed at intervals of 2, 4,
and 6 weeks.
(legend continued on next page)
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IPA-3 treatment significantly inhibited the presence of activated
nuclear Stat5 in FLT3ITD-expressing cells. As seen in Figure 8A
(lane 1 versus 2), addition of ligand also resulted in activation of
the Stat5 oncogenic pathway in FLT3WT cells, which was also
inhibited by IPA-3 (Figure 8A, lane 4). Next, we used another
PAK inhibitor PF-3758309 (PF) (Murray et al., 2010). As seen in
Figure 8B (lane 1 versus 2), similar results were observed upon
treating FLT3ITD cells with PF-3758309, resulting in repression
of nuclear translocation of active Stat5. Consistent with these re-
sults, expression of a dominant-negative form of PAK1 (K299R)
in FLT3ITD-expressing cells (Figure S5F) demonstrated reduced
tyrosine-phosphorylated Stat5 (Figure S5E). These results sug-
gest that, downstream from Rac1, PAK contributes to the trans-
location of active Stat5 in the nucleus in FLT3ITD-bearing cells.
To determine whether PAK is active in FLT3ITD and KITD814V
oncogene-bearing cells, whole-cell lysates were analyzed for
PAK1 activity. As seen in Figure S6A, cells expressing KITD814V
showed increased levels of constitutive PAK1 activation (pPAK1)
compared to KITWT cells (lane 1 versus 5), which was readily in-
hibited upon treatment with F-14 (lane 2 versus 6). Similar results
were seen in FLT3ITD-expressing cells treated with F-14 (Fig-
ure S6B, lane 1 versus 2). Inhibition of active PAK1 levels was
also observed in FLT3ITD-expressing cells treated with PAK in-
hibitors IPA-3 and PF-3758309 (Figure S6C, lane 1 versus 2
and 3). These results suggest that PAK1 is hyperactive down-
stream of a FAK/Rac1-signaling pathway in FLT3ITD and
KITD814V oncogene-bearing cells.
Group I family of PAKs consist of three members including
PAK1, PAK2, and PAK3. Whereas PAK1 and PAK2 are ubiqui-
tously expressed, PAK3’s expression is predominantly restricted
to the brain (Ye and Field, 2012). We assessed the role of PAK1
and PAK2 in oncogene-induced transformation by examining
Stat5 activation in FLT3ITD cells in which the expression of these
two isoforms was knocked down (Figure S6E). As seen in Fig-
ure S6D, knockdown of PAK1 (lane 1 versus 2 and 3), but not
PAK2 (lane 1 versus 4–6), significantly reduced the nuclear accu-
mulation of active Stat5 in FLT3ITD-expressing cells. Consistent
with these findings, expression of FLT3ITD in PAK1-deficient BM
(PAK1/) cells also impaired the nuclear translocation of active
Stat5 (Figure S6I, lane 1 versus 2). Furthermore, loss of active
Stat5 nuclear import in PAK1/ FLT3ITD cells resulted in
reduced expression of Stat5 target genes including Bcl-xL and
c-Myc compared to controls (Figure S6F) and also reduced rela-
tive mRNA levels of c-Myc and BclXL in FLT3ITD cells treated
with PAK inhibitor PF-3758309 (Figures 8C and 8D).
Inhibition of PAK1 Delays the Onset of FLT3ITD- and
KITD814V-Induced MPN and Prolongs the Survival
of Mice
To determine the role of PAK isoforms in FLT3ITD- and
KITD814V-mediated MPN development, BM transplant studies(E and F) After 6 weeks, mice were harvested to determine spleen size (E) and w
(G) 5-FU-treated BM cells from WTFAK or FAK/ mice expressing KITD814V w
(H and I) Kaplan-Meier survival analysis of FAK+/+ KITD814V (n = 9) versus FAK
(J) Secondary transplants were performed using BM from FAK+/+ KITD814V and
(K and L) Kaplan-Meier survival analysis of FAK+/+ KITD814V (n = 5) versus FA
(L; *p < 0.05).
Cell Rewere performed. Transplantation studies utilizing myeloid cells
bearing FLT3ITD in the context of PAK2 knockdown did not
prolong the survival of leukemic mice compared to controls (Fig-
ure S6G). In contrast, PAK1 knockdown in the context of
FLT3ITD expression significantly enhanced the lifespan of
leukemic mice (Figure S6H). To further confirm PAK1’s involve-
ment in KITD814V-mediated leukemogenesis, we transplanted
mice with KITD814V-bearing PAK1/ BM cells or WT
(PAK1+/+) controls. Mice transplanted with WTPAK1 BM cells
expressing KITD814V came down with disease significantly
earlier than PAK1/ KITD814Vmice (Figure 8G), at which junc-
ture time-point-matched control mice (PAK1/ KITD814V,
PAK1+/+ KITWT, and PAK1/ KITWT) were euthanized and
BM (Figure 8E) and spleen (Figure 8F) cells harvested and sub-
jected to cellular fractionation analysis. As seen in Figures 8E
(lane 1 versus 2) and 8F (lane 1 versus 2), similar to our data
with cell lines and PAK inhibitors, genetic ablation of PAK1 in vivo
abrogated the nuclear translocation of active Stat5 in KITD814V-
bearing BM-derived cells. As seen in Figure 8G, genetic abla-
tion of PAK1 significantly prolonged the survival of leukemic
mice (PAK1/ KITD814V) compared to controls (PAK1+/+
KITD814V) and modulated the development of MPN in mice as
shown by reduced splenomegaly and WBC counts (Figures
8H, S6J, and S6K). Mice transplanted with WTKIT did not
demonstrate any signs of MPN and showed normal survival
and spleen size (Figures 8H and S6J). To further ascertain
whether targeting PAK1 in the context of KITD814V-induced
MPN selectively impacts the leukemia initiating cell ‘‘LIC’’ popu-
lation, we performed secondary transplants using BM cells
from primary recipients. As seen in Figure 8I, mice transplanted
with BM cells from primary donor harboring KITD814V in a
PAK1-deficient background (PAK1/ KITD814V) survived
significantly longer than mice transplanted with BM from WT
background (PAK1+/+ KITD814V). The survival of mice corre-
lated with correction in spleen size (Figures 8I, 8J, and S6L),
similar to primary transplants described above.
Inhibition of PAK Inhibits the Constitutive Growth
of FLT3ITD+ AML Cells and KITD816V (+)
SM-Patient-Derived Cells
To assess the functional consequence(s) of PAK1 repression on
the growth and transforming ability of FLT3ITD- and KITD814V-
bearing cells, we performed a proliferation assay using cells
expressing FLT3 and KIT receptors treated with or without
PF-3758309. A dose-dependent reduction in the growth of
FLT3ITD- and KITD814V-bearing cells was observed, but
not that of FLT3WT- and KITWT-bearing cells (Figures S7A,
S7B, S7C, and S7D, respectively). Similar results were ob-
served for FLT3ITD cells treated with the PAK inhibitor IPA-3
(Figure S7E). To further validate these observations, we per-
formed similar studies in FLT3ITD-bearing cells coexpressing aeight (F).
ere transplanted into lethally irradiated C57BL/6 mice.
/ KITD814V (n = 9) mice; spleen size (H) and weight (I) is shown (*p < 0.002).
FAK/ KITD814V primary recipients.
K/ KITD814V (n = 5) is shown (*p < 0.003) and spleen size (K) and weight
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Figure 8. In Vivo Inhibition of PAK1 Delays the Onset of MPN in Mice Transplanted with KITD814V-Bearing Cells
(A) 32D cells expressing FLT3ITD or FLT3WT were starved of serum and treated with the PAK inhibitor IPA-3 (lanes 3 and 7) alone, with FL (lanes 2 and 6), or with
IPA-3 followed by FL (lanes 4 and 8) as indicated and subjected to cellular fractionation assay. Nuclear and cytosolic fractions were quantitated, and equal lysates
were loaded on a gel and probed with the indicated antibodies. Arrows indicate the activation/expression of the labeled molecules in nuclear as well as in
cytosolic fractions of FLT3ITD- and FLT3WT-bearing cells. Expression of PARP-1 was used as an indicator of nuclear loading (n = 2).
(B) 32D FLT3ITD and FLT3WT were serum starved and treated with the PAK inhibitor PF-3758309 (PF) and analyzed as described in (A).
(legend continued on next page)
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dominant-negative version of PAK1 (K299R; Figure S7F) as well
as in BM cells expressing FLT3ITD in the setting of PAK1 defi-
ciency (Figure S7G). A significant inhibition in the growth of
FLT3ITD-bearing cells was noted in the background of domi-
nant-negative or genetic ablation of PAK1. A similar inhibition
in the growth of AML patient cells (Figure S7I) and KITD816V
(+) SM-patient-derived cells (Figure S7K) was observed in the
presence of IPA-3. Lastly, we assessed the role of PAK1 overex-
pression on the rescue of ligand-independent growth of BM cells
expressing KITD814V in PAK1-deficient (PAK1/) back-
ground. An activated version of PAK1 (PAK1T423E; Schu¨rmann
et al., 2000) was coexpressed with KITD814V in BM cells de-
rived from PAK1/ mice. As seen in Figure S7H, we observed
rescue of ligand-independent growth of cells overexpressing
PAK1T423E, as compared to vector control.
DISCUSSION
Presence of active Stat5 in the nucleus and the subsequent
expression of Stat5-dependent prosurvival and antiapoptotic
genes plays a key role in the transformation of cells bearing onco-
genic forms of FLT3 and KIT (Benekli et al., 2003; Choudhary
et al., 2007; Tse et al., 2000). However, the mechanism(s)
involved in regulating the active form of nuclear Stat5 remain
poorly understood. To this end, a role for Rac1GTPase/MgcRac-
GAP complex in the translocation of active Stat5 into the nucleus
has been suggested; however, the upstream and downstream
signaling proteins from Rac1 involved in this process have not
been identified and the extent to which these proteins contribute
to leukemogenesis is unknown (Sallmyr et al., 2008). Using phar-
macologic, biochemical, and genetic approaches, we demon-
strate that the FAK/Rac1-Tiam1/PAK1 axis plays a crucial role
in the transformation induced by oncogenic forms of FLT3
(FLT3ITD) and KIT (KITD816V). Targeting FAK, Tiam1, and
PAK1 in oncogene-bearing cells in vitro or in vivo inhibits the
presence of active Stat5 in the nuclear compartment, which pro-
foundly delays the onset of leukemia by repressing the expres-
sion of Stat5-responsive genes. These findings were validated
in both murine and humanmodels of AML andMPN and suggest
that the signaling axis we have identified is highly conserved
across species.More importantly, we show that this axis is active
in leukemia-initiating cells aswell as in leukemic cells that acquire
AC220-resistant mutations of FLT3.
We and others have shown that FAK may contribute to Rac
activation in hematopoietic cells as well as in other heterologous
cell systems (Chang et al., 2007; Elias et al., 2010; Vemula et al.,(C and D) qRT-PCR analysis of relative mRNA expression levels of Stat5-respon
PF-3758309 (n = 2); *p < 0.05.
(E and F) Fractionation assays were performed in BM cells (E) and splenocytes (F).
PAK1-deficient (PAK1/ KITD814V) cells (n = 2). The level of phospho-Stat5
Expression of GAPDH was used as an indicator of cytosolic marker and loading
(G and H) Primary transplants were carried out using 5-FU-treated BM cells from
planted into lethally irradiated C57BL/6mice. Four groups ofmice were used:WTP
PAK1/KITWT (n = 5). Kaplan-Meier survival analysis ofPAK1+/+KITD814V ver
significant overall survival (*p < 0.0003; Hom-Sidak method) and significant redu
(I and J) Secondary transplants were performed with BM cells from PAK1+/+ KITD
mice. Kaplan-Meier survival analysis of PAK1+/+ KITD814V (n = 5) versus PAK1
significant reduction of spleen size (J).
Cell Re2010) and that FLT3ITD can activate Rac1 and regulate the
production of reactive oxygen species (ROS) via its association
with Stat5 (Sallmyr et al., 2008). Furthermore, active Rac1 can
also induce the activation and nuclear translocation of Stat3
(Simon et al., 2000). FLT3ITD can phosphorylate Stat5, in-
dependent of Jak kinase family members (Choudhary et al.,
2007), whereas Rac1-mediated ROS production can induce
the activation of Jak kinases and Stats downstream of G-pro-
tein-coupled receptors (Pelletier et al., 2003). Although signifi-
cant work has been done in identifying the above described
linkages, how these molecules connect and what is their rela-
tionship in regulating transformation via oncogenic forms of
KIT and FLT3 has never been described. Our findings provide
insight into how FAK-Rac1-Tiam1 and PAK1 axis contributes
to leukemic transformation in part by regulating active nuclear
Stat5.
The role of GEFs such as Vav1 and Vav2 is largely considered
promiscuous, as they regulate the activity of all three members
of the Rho GTPase family including Rac, Rho, and Cdc42
(Schmidt and Hall, 2002). In contrast, GEF Tiam1 is highly spe-
cific for Rac1 in vivo and has been implicated in activating Rac1
to mediate Stat3 activation and its subsequent nuclear localiza-
tion in COS-1 cells (Simon et al., 2000). We demonstrate that
FAK activates Rac1 via Rac GEF Tiam1 in FLT3ITD-bearing
cells and targeting FAK and Tiam1 results in inhibition of
Rac1. We also show that shRNA-mediated knockdown of
Tiam1 prolongs the survival of FLT3ITD-bearing leukemic mice
and genetic and pharmacologic inhibition of FAK and Tiam1 re-
sults in failure of active Stat5 to be expressed in the nucleus,
along with Rac1. Whereas Tiam1 regulates epithelial cancers
such as carcinomas of breast and colon (Bourguignon et al.,
2000; Buongiorno et al., 2008), we show its role in regulating he-
matologic malignancies.
Although evidence in this study and reported earlier (Sallmyr
et al., 2008) suggests a role of Rac1 in translocating Stat5 into
the nucleus, the relationship between Stat5 and Rac GTPases
in the context of FLT3 and KIT oncogenic mutations is unclear.
An indirect role of PAK1 in nuclear shuttling of Stat5 has been
suggested, where PAK1 plays a role in ‘‘switching’’ in occupancy
of the same promoter region between BCL6 and Stat5. In colo-
rectal cancer, PAK1, activated via Rac1, translocates into the nu-
cleus and phosphorylates chromatin-bound BCL6, leading to its
dissociation from the promoter, thereby allowing active Stat5
that is already present in the nucleus via a Rac1/MgcRacGAP-
dependent mechanism to bind to the same promoter regions
(Barros et al., 2012). In line with reported findings by Barrossive genes BclXL (C) and c-Myc (D) in FLT3ITD cells treated with PAK inhibitor
Mice cohorts transplanted with KITD814V in aWT PAK1 (PAK1+/+ KIT814V) or
and total Stat5 and Rac1 in the nuclear and cytosolic fractions is indicated.
control. MK denotes lane with protein ladder.
WTPAK1 or PAK1/ mice transduced with KITD814V or KITWT and trans-
AK1 KITD814V (n = 8); WTPAK1 KITWT (n = 5);PAK1/KITD814V (n = 8); and
sus PAK1/KITD814V,WTPAK1KITWT, andPAK1/KITWTmice showed
ction of spleen size (H).
814V and PAK1/ KITD814V mice and transplanted into irradiated C57BL/6
/ KITD814V (n = 5) mice showed significant overall survival (*p < 0.001) (I) and
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et al., we have observed a reduction in BCL6 activation and its
mRNA expression levels upon treatment of FLT3ITD cells with
PAK1 inhibitor (Figures S8A and S8B). These data demonstrate
that, in the FLT3 and KIT oncogenic pathway, the FAK/Tiam1/
Rac1-signaling axis activates PAK1, which in turn inhibits the
transcriptional repressor BCL6, while correspondingly activating
Stat5 to mediate leukemic transformation.
In BCR-ABL-induced CML, majority of Stat5 is persistently
active and retained in the cytoplasmic compartment, primarily
via an association of active Stat5withGab2 andPI3K/Akt, subse-
quently leading to leukemogenesis (Nyga et al., 2005). FLT3ITD
also interacts with Gab2 and results in the activation of PI3K/
Akt-; Stat5- and Gab2-mediated recruitment of Src kinases can
also result in the activation of Stat5. Thus, whereas FLT3ITD
can directly activate Stat5 (Choudhary et al., 2007), other tyrosine
kinases present in complexes with FLT3ITDmay also be involved
in regulating Stat5 activation including Src kinases, as mutating
Src-kinase-binding sites Y589 and Y591 in FLT3 receptor inhibits
Stat5 activation (Hayakawa et al., 2000; Rocnik et al., 2006). Our
data using FLT3ITD specific inhibitor AC220 not only show inhibi-
tion in the phosphorylation of FLT3ITD on Y589/591 but also
downstream inhibition of activating residue Y397 on FAK, indi-
cating that oncogenic FLT3 mediates direct activation of FAK.
In breast cancer cells, prolactin (PRL)-induced activation of
FAK and Stat5 is mediated via Src family kinases. Upon phos-
phorylation by Src, phosphorylated FAK recruits Grb2/Gab2 to
mediate activation of Ras/MAPK-signaling pathway. The involve-
ment of the PI3K/Rac/Pak pathway in PRL-induced activation of
Erk has also been suggested. These results demonstrate a com-
plex crosstalk between various signaling pathways involved in
breast cancer metastasis (Aksamitiene et al., 2011). Future
studies will determine whether Gab2 or other Src kinases play
a role in activating FAK downstream of FLT3ITD and KITD814V
receptors, which results in oncogenic transformation mediated
by the subsequent nuclear translocation of active Stat5.EXPERIMENTAL PROCEDURES
Antibodies and Reagents
Phycoerythrin-conjugated annexin V antibody and 7-amino actinomycin D
were purchased from BD Biosciences PharMingen. Rabbit anti-phospho-
PAK1, anti-PAK1, anti-phospho-Stat5 (Y694), anti-Stat5 antibodies, rabbit
anti-phospho-FAK (Y397), and anti-FAK antibodies were purchased from
Cell Signaling Technology. Anti-rabbit immunoglobulin G DyLight 649 from
Biolegend, Anti-actin and GAPDH antibodies were purchased from Sigma.
Tiam1 activation kit was purchased from Cell BioLabs. Anti-mouse-horse-
radish peroxidase (HRP), anti-rabbit-HRP, anti-goat-HRP, anti-phospho-
Stat5 (S780), anti-Tiam1, PARP-1, LaminB, BclXL, and cMyc antibodies
were purchased from Santa Cruz Biotechnology. FAK inhibitors F-14 and Y-
11, PAK inhibitors IPA-3 and PF-3758309, and Rac inhibitor NSC23766 were
purchased from R&D Systems. Lumina Forte Western HRP Substrate, Chemi-
luminescent Blocker (bløk-CH), anti-phospho-FAK (Y397) rabbit polyclonal,
anti-Rac1 (23A8), and Rac1 activation kit were purchased from Millipore. Re-
combinant murine and human IL-3, Flt3, granulocyte macrophage-colony
stimulating factor, stem cell factor, IL-6, and Tpo were purchased from Pepro-
tech. Retronectin was obtained from Takara. Iscove’s modified Dulbecco’s
medium was purchased from Invitrogen. Monothioglycerol was purchased
from Sigma. [3H]thymidine was purchased from PerkinElmer. Protein A-Se-
pharose beads were purchased from Amersham Biosciences. MKK/MEK in-
hibitor PD98059 was purchased from Cell Signaling Technology, Raf inhibitor
PLX4720 from Selleckchem, and Akt inhibitor 124005 from Millipore.1346 Cell Reports 9, 1333–1348, November 20, 2014 ª2014 The AutMice
C57BL/6 and C3H/HeJ mice were purchased from Jackson Laboratory. FAK-,
Rac1-, and PAK1-deficient mice have been previously described (Martin et al.,
2013; McDaniel et al., 2008; Vemula et al., 2010). All mice used in this study
were between 6 and 12 weeks of age and were maintained under specific
pathogen-free conditions at the Indiana University Laboratory Animal
Research Center. The studies were approved by the Institutional Animal
Care and Use Committee of the Indiana University School of Medicine.
Patient Samples
Peripheral blood mononuclear cells from patients with AML were obtained at
the time of diagnostic testing after informed consent. Approval was obtained
from the institutional review boards of Indiana University School of Medicine.
The buoyant fraction was isolated over Ficoll-Hypaque and then washed
with PBS before processing as described previously (Hartman et al., 2006).
KITD816V-positive or negative SM-patient-derived cells were obtained as
described (Traina et al., 2012).
Cells
Primary low-density mononuclear cells were harvested as described earlier
and used in the study (Mali et al., 2011). The murine IL-3-dependent myeloid
cell line 32D cells bearing FLT3, FLT3ITD (N51), MIEG3 vector, KIT, or
KITD814V have been described (Mali et al., 2011). Puromycin-resistant BaF3
cells bearing the AC220-resistant mutants (Flt3ITD+TKD_D835Y/F and
F691L) have been described (Smith et al., 2012). The humanmast cell leukemia
line, bearing the KITV560G as well as KITD816V mutations, HMC1.2 and AML
cell line, bearing the FLT3ITD mutation, MV4-11 have been described (Butter-
field et al., 1988; Lange et al., 1987).
Expression of WT and Oncogenic Receptors
Transduction of 32D and primary BM-derived hematopoietic stem and pro-
genitor cells was performed as described previously (Mali et al., 2011).
shRNA Silencing of FAK, Tiam1, and PAK
FAK-, Tiam1-, or PAK-specific shRNA expression plasmids were purchased
from OriGene Technologies. Purified and sequence-verified plasmid contain-
ing a noneffective 29 mer shGFP cassette (Scrambled vector) was used as a
negative control. Cells were transduced with scrambled vector or shRNA
plasmid and grown in the presence of puromycin (10 ng/ml) to select for the
transduced cells.
Proliferation and Apoptosis Assays
Proliferation assays were performed as previously described (Mali et al., 2011).
Cytoplasm and Nuclear Extraction
To extract nuclear and cytosolic fractions, the NE-PER Nuclear and Cyto-
plasmic Extraction Kit (Thermo Scientific) was used as per the manufacturer’s
instructions.
IP and WB
Immunoprecipitation (IP) and western blot analysis (WB) was performed as
described previously (Mali et al., 2011).
qRT-PCR
Total RNAwas isolated from 53 106 cells using RNeasy PlusMini Kit (QIAGEN)
according to the manufacturer’s instructions. cDNA was generated using
random hexamer primers and Superscript II reverse transcriptase (Invitrogen).
qRT-PCR was performed using FastStart Universal SYBR Green master mix
(Roche) and a Applied Biosystem 7500 Real Time PCR system. b-actin ampli-
fication was used to normalize sample RNA content.
Mouse Leukemia Induction and In Vivo Drug Treatment
Mouse leukemia induction and in vivo drug treatments were performed as
described previously (Mali et al., 2011). We injected 13 106 32D cells bearing
FLT3ITD in 200 ml PBS into C3H/HeJ mice intravenously. After 48 hr of trans-
plantation, mice were treated with vehicle (PBS/DMSO) or FAK inhibitor F-14
(25 mg/kg body weight) by intraperitoneal injection at 24 hr interval forhors
21 days. Mice were closely monitored for MPN development and harvested at
moribund. For F-14 treatment in a primary transplant model, irradiated BoyJ
micewere transplanted with 2.03 106 GFP-KITD814V cells and 0.13 106 sup-
porting BMcells. Three weeks posttransplant mice were treatedwith 10mg/kg
body weight F-14 for 5 days a week for 6 weeks. All mice were harvested, and
peripheral blood (PB) counts were monitored using a Hemavet 950 (Drew Sci-
entific). PB, BM, and spleens were analyzed for GFP expression. BM, spleen,
and lungs were also fixed in 10% buffered formalin to perform histopathologic
analysis by hematoxylin and eosin staining.
Primary and Secondary Bone Marrow Transplants
Eight- to ten-week-oldC57BL/6,PAK1/, orFAK/micewere injectedwith
5-flurouracil (150mg/kgbodyweight), andafter 5 days, themicewere killedand
BMwas harvested. Cells were prestimulated overnight in Iscove modified Dul-
becco medium supplemented with 20% fetal bovine serum with mouse SCF
(100 ng/ml), mouse TPO (100 ng/ml), mouse Flt3 (50 ng/ml), and mouse IL-6
(10 ng/ml). Cells were plated on Retronectin-coated plates (Takara), and retro-
viral transduction was performed using viral supernatants as described before
(Mali et al., 2011). GFP+ve cells were sorted using FACSAria (BDBiosciences).
We injected 13 106 GFP-positive cells alongwith 0.13 106 supporting spleno-
cytes into the tail veins of lethally irradiated (11 Gy) female C57BL/6 recipient
mice. Peripheral blood counts were monitored on a regular interval after trans-
plantation on a Hemavet 950 (Drew Scientific) and by fluorescence-activated
cell sorting analysis for GFP expression. All moribund mice were then eutha-
nized, and peripheral blood, BM, and spleen cells were analyzed for GFP
expression. At day 120, all remaining mice were euthanized and analyzed.
For secondary transplant, leukemic WT mice and time-point-matched
PAK1/ or FAK/ mice, both bearing KitD814V-expressing cells, were
harvested and 13 106 cells were injected into the tail veins of lethally irradiated
(11 Gy) female C57BL6 recipients.
Statistics
All graphical data were evaluated by paired Student’s t test (two-tailed), and
results were considered significantly different with p value < 0.05. All data
are represented as mean values ± SD. Survival probability of transplanted
mice groups was compared using a Kaplan-Meier survival analysis in which
statistical significance was determined as p values < 0.05 by log rank test.
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